NCT04224350 - Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM) | Biotech Hunter

Enrollment

184

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

July 30, 2020

Study Completion Date

November 30, 2020

Conditions

Kidney Transplant

Interventions

DRUG

TacroBell SR cap.

"* Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment."

DRUG

Tacrolimus cap.

"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."

Trial Locations (1)

Unknown

RECRUITING

The Catholic University of Korea, Seoul, St.Mary's Hospital., Seoul